Intravenous immune globulin in chronic lymphocytic leukaemia.
The most common complication of chronic lymphocytic leukaemia (CLL) is infection, which occurs mainly in advanced stages of disease or in those patients with hypogammaglobulinaemia. Intravenous immune globulin (IVIG) has been shown to be a useful prophylactic therapy against infections in such patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
1994
|
| _version_ | 1797064987296923648 |
|---|---|
| author | Gamm, H Huber, C Chapel, H Lee, M Ries, F Dicato, M |
| author_facet | Gamm, H Huber, C Chapel, H Lee, M Ries, F Dicato, M |
| author_sort | Gamm, H |
| collection | OXFORD |
| description | The most common complication of chronic lymphocytic leukaemia (CLL) is infection, which occurs mainly in advanced stages of disease or in those patients with hypogammaglobulinaemia. Intravenous immune globulin (IVIG) has been shown to be a useful prophylactic therapy against infections in such patients. A randomized, double-blind study on 36 patients receiving either 500 mg/kg or 250 mg/kg IVIG every 4 weeks was undertaken to determine the dose regimen required. There was no significant difference in the two treatment groups and we found that CLL patients were equally protected with low-dose IVIG. |
| first_indexed | 2024-03-06T21:22:10Z |
| format | Conference item |
| id | oxford-uuid:41cebeee-daf5-4943-965f-f27bd9c74a63 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:22:10Z |
| publishDate | 1994 |
| record_format | dspace |
| spelling | oxford-uuid:41cebeee-daf5-4943-965f-f27bd9c74a632022-03-26T14:45:58ZIntravenous immune globulin in chronic lymphocytic leukaemia.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:41cebeee-daf5-4943-965f-f27bd9c74a63Symplectic Elements at Oxford1994Gamm, HHuber, CChapel, HLee, MRies, FDicato, MThe most common complication of chronic lymphocytic leukaemia (CLL) is infection, which occurs mainly in advanced stages of disease or in those patients with hypogammaglobulinaemia. Intravenous immune globulin (IVIG) has been shown to be a useful prophylactic therapy against infections in such patients. A randomized, double-blind study on 36 patients receiving either 500 mg/kg or 250 mg/kg IVIG every 4 weeks was undertaken to determine the dose regimen required. There was no significant difference in the two treatment groups and we found that CLL patients were equally protected with low-dose IVIG. |
| spellingShingle | Gamm, H Huber, C Chapel, H Lee, M Ries, F Dicato, M Intravenous immune globulin in chronic lymphocytic leukaemia. |
| title | Intravenous immune globulin in chronic lymphocytic leukaemia. |
| title_full | Intravenous immune globulin in chronic lymphocytic leukaemia. |
| title_fullStr | Intravenous immune globulin in chronic lymphocytic leukaemia. |
| title_full_unstemmed | Intravenous immune globulin in chronic lymphocytic leukaemia. |
| title_short | Intravenous immune globulin in chronic lymphocytic leukaemia. |
| title_sort | intravenous immune globulin in chronic lymphocytic leukaemia |
| work_keys_str_mv | AT gammh intravenousimmuneglobulininchroniclymphocyticleukaemia AT huberc intravenousimmuneglobulininchroniclymphocyticleukaemia AT chapelh intravenousimmuneglobulininchroniclymphocyticleukaemia AT leem intravenousimmuneglobulininchroniclymphocyticleukaemia AT riesf intravenousimmuneglobulininchroniclymphocyticleukaemia AT dicatom intravenousimmuneglobulininchroniclymphocyticleukaemia |